Myelodysplastic Syndrome with Excess Blasts

Myelodysplastic Syndrome with Excess Blasts — Trials · CancerIndex

Clinical trials

Registered studies

76 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 23
Recruiting: 12
Ph III recruiting: 0
Growth YoY: —
Industry share: 17%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (9)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02530034	Hu8F4 in Treating Patients With Advanced Hematologic Malignancies	active not recruiting	Phase 1	72	M.D. Anderson Cancer CenterOTHER	1	Sep 18, 2026	clinicaltrials
NCT03816319	TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts	active not recruiting	Phase 1	42	National Cancer Institute (NCI)NIH	2	Sep 16, 2026	clinicaltrials